Company Overview of Scioderm, LLC
Scioderm, LLC researches, develops, and manufactures drugs for the treatment of patients with epidermolysis bullosa (EB). It offers Zorblisa, an investigational therapy for the treatment of skin blistering and lesions associated with EB, a rare group of inherited disorders that manifest as blistering or erosion of the skin, and the epithelial lining of other organs. The company’s Zorblisa facilitates the healing of skin lesions and reduction of the incidence and/or severity of new lesions. The company was founded in 2012 and is based in Durham, North Carolina. As of September 30, 2015, Scioderm, LLC operates as a subsidiary of Amicus Therapeutics, Inc.
1007 Slater Road
Durham, NC 27703
Founded in 2012
Key Executives for Scioderm, LLC
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Scioderm, LLC, please visit www.sderm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.